Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency. Its preclinical programs include INBRX-106, a single domain antibody based hexavalent agonist of OX40 for a range of oncology indications. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California.
IPO Year:
Exchange: NASDAQ
Website: inhibrx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/23/2024 | Mkt Perform | JMP Securities | |
| 1/23/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 3/16/2022 | $40.00 | Outperform | SMBC Nikko |
| 3/2/2022 | $53.00 → $40.00 | Market Outperform | JMP Securities |
| 11/10/2021 | $44.00 → $53.00 | Outperform | Credit Suisse |
| 11/2/2021 | $46.00 → $53.00 | Market Outperform | JMP Securities |
| 9/21/2021 | $46.00 | Market Outperform | JMP Securities |
SAN DIEGO, Oct. 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that, based on discussions with the U.S. Food and Drug Administration (FDA), there is potential to pursue an accelerated approval in the U.S. for INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD) using functional alpha-1 antitrypsin (AAT) serum levels as the surrogate endpoint. Inhibrx also announced the detection of INBRX-101 in the bronchoalveolar lavage fluid (BALF) samples from all AATD patients teste
Topline results from the Phase 1 study showed a favorable safety and tolerability profile with no drug-related severe or serious adverse events.Topline data from the multiple ascending dose cohorts of 40, 80 and 120 mg/kg demonstrated the average level ("Cavg") of functional alpha-1 antitrypsin ("AAT") achieved by INBRX-101 was 40.4 micromolar ("µM") over the 21-day dosing interval following the third 80 mg/kg dose. Functional AAT levels collected from 65 healthy individuals with the MM genotype revealed a 5th/95th percentile range of 23 to 57 µM and a median of 38 µM.SAN DIEGO, May 16, 2022 /PRNewswire/ -- Inhibrx Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in de
SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, today announced interim results from a Phase 1 clinical trial evaluating the safety and pharmacokinetics of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency, or AATD. Interim functional PK data from this multi-country multi-center Phase 1 study are from 21 patients with AATD, all with the ZZ mutation of the SERPINA1 gene, the underlying caus
SC 13G - Inhibrx Biosciences, Inc. (0002007919) (Subject)
SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)
SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)
SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)
SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)
SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)
SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)
SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)
SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)
SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), announced the appointment of three key executives: David Matly, M.B.A., as Chief Commercial Officer; David Kao, PharmD, M.B.A., RPh, as Vice President of Regulatory Affairs; and Jack Tsai, M.D., M.B.A., as Vice President of Business Development. "The additions of David, David and Jack come at an important time for Inhibrx, as our pipeline demonstrates meaningful clinical activity in areas of high unmet medical need such as Alpha-1 Antitrypsin Deficiency and Chondrosarcoma. We are building a seasoned, world-
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx, Inc. (0001739614) (Reporting)
424B3 - Inhibrx Biosciences, Inc. (0002007919) (Filer)
8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
10-Q - Inhibrx Biosciences, Inc. (0002007919) (Filer)
424B3 - Inhibrx Biosciences, Inc. (0002007919) (Filer)
8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
424B3 - Inhibrx Biosciences, Inc. (0002007919) (Filer)
424B3 - Inhibrx Biosciences, Inc. (0002007919) (Filer)
8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
10-Q - Inhibrx Biosciences, Inc. (0002007919) (Filer)
S-8 POS - Inhibrx, Inc. (0001739614) (Filer)
JMP Securities initiated coverage of Inhibrx Biosciences with a rating of Mkt Perform
JMP Securities downgraded Inhibrx from Mkt Outperform to Mkt Perform
SMBC Nikko initiated coverage of Inhibrx with a rating of Outperform and set a new price target of $40.00
JMP Securities reiterated coverage of Inhibrx with a rating of Market Outperform and set a new price target of $40.00 from $53.00 previously
Credit Suisse reiterated coverage of Inhibrx with a rating of Outperform and set a new price target of $53.00 from $44.00 previously
JMP Securities reiterated coverage of Inhibrx with a rating of Market Outperform and set a new price target of $53.00 from $46.00 previously
JMP Securities initiated coverage of Inhibrx with a rating of Market Outperform and set a new price target of $46.00
Credit Suisse resumed coverage of Inhibrx with a rating of Outperform and set a new price target of $44.00
Credit Suisse Group reiterated coverage of Inhibrx with a rating of and set a new price target of $44.00 from $28.00 previously
SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third quarter of 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx Biosciences business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the next 12 months. Because the spin-off was accounted for as a reverse spin-off, for periods prior to the spin-off, the Company's financial statements are the historical financial statements of
SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, is pleased to announce a decisive legal victory in a trade secrets case brought by I-Mab Biopharma ("I-Mab") in the United States District Court for the District of Delaware. The jury found in favor of Inhibrx, rejecting all allegations of misappropriation before it, confirming the Company's adherence to high ethical standards and innovation in scientific research.
SAN DIEGO, Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2024 and provided an update on recent corporate highlights. Separation from the Former Parent In January 2024, Inhibrx, Inc. (the "Former Parent") announced its intent, as approved by its board of directors, to effect the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT
SAN DIEGO, May 24, 2024 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved the sale to Sanofi of all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD"). Immediately prior to the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline and its corporate infrastructure, will be spun out from the Company
SAN DIEGO, May 10, 2024 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"), the Nasdaq Global Market ("Nasdaq") informed the Company that Nasdaq intends to permit the commencement of the trading of the shares of SpinCo common stock on a "when-issued" basis after the stockholders of the Company approve the acquisition of the Company by Sanofi (the "Merger") at the Company's special meeting of stockholders,
SAN DIEGO, May 8, 2024 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. ("SpinCo"), to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"). The Company also announced that the distribution in the Spin-Off is expected to occur at 11:59 p.m., Eastern Time, on May 29, 2024 (the "Distribution Time") and the clo
SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023. Key Highlights Sale of INBRX-101 to Sanofi: In January 2024, the Company announced that it entered into a definitive agreement with Aventis, Inc. ("Aventis"), a subsidiary of Sanofi, whereby Sanofi will indirectly acquire, through Aventis, all of the assets and liabilities associated with INBRX-101 ("
Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets of Inhibrx, Inc. Sanofi to pay off Inhibrx's outstanding debt balance and capitalize New Inhibrx with $200 million in cash SAN DIEGO, Jan. 23, 2024 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX) ("Inhibrx," or the "Company") and Sanofi (NASDAQ:SNY) ("Sanofi") today announced that the companies have entered into a definitive agreement under which Aventis Inc., a Pennsylvania corporation (a subsidiary of Sanofi) will acquire all the assets and liabilities associated with INBRX-101, an optimized,
SAN DIEGO, Sept. 19, 2023 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that Chiesi Farmaceutici S.p.A ("Chiesi") declined to exercise its option for the ex-North American rights to develop and commercialize INBRX-101 for the treatment of patients with emphysema due to Alpha-1 Antitrypsin Deficiency ("AATD"). Inhibrx's delivery of the European Medicines Agency ("EMA") scientific advice to Chiesi triggered a 60-day option period to obtain an exc
SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has entered into a securities purchase agreement for a private placement financing (the "PIPE") that is expected to result in gross proceeds of approximately $200 million. The financing was limited to certain of the Company's existing investors, which included participation from RA Capital Management as the lead investor, Viking Global Investors, Perceptive Advisors, and TCGX.
JMP Securities analyst Reni Benjamin initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Market Perform rating.
– SEC Filing
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold players in this sector, having an RSI near or below 30. Inhibrx Biosciences, Inc. (NASDAQ:INBX) On May 24, Inhibrx stockholders approved sale of INBRX-101 to Sanofi. The company's s
Inhibrx (NASDAQ:INBX) reported quarterly losses of $(1.73) per share which missed the analyst consensus estimate of $(1.04) by 66.35 percent. The company reported quarterly sales of $1.63 million which beat the analyst consensus estimate of $50.00 thousand by 3.17K percent. This is a 496.35 percent increase over sales of $274.00 thousand the same period last year.
Sanofi SA (NASDAQ:SNY) has agreed to acquire assets and liabilities associated with Inhibrx Inc’s (NASDAQ:INBX) INBRX-101, an optimized, recombinant alpha-1 antitrypsin augmentation therapy currently in a registrational trial for alpha-1 antitrypsin deficiency. Immediately before the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx’s non-101 discovery pipeline, and its corporate infrastructure, will be spun out from Inhibrx into a new publicly traded company, Inhibrx Biosciences Inc (New Inhibrx). Under the terms of the agreement, Sanofi will acquire all outstanding shares of Inhibrx through a merger for $30.00 per share in c
In a strategic move to bolster its rare disease business, Sanofi SA (NASDAQ:SNY) has agreed to acquire the drug development project INBRX-101 from its parent company, Inhibrx Inc (NASDAQ:INBX). This acquisition is valued at approximately $2.2 billion. What Happened: The French healthcare company announced the acquisition on Tuesday, as reported by Reuters. The deal includes a cash payment of $30 per share to Inhibrx shareholders, along with a contingent value right (CVR) of $5 and 0.25 shares in New Inhibrx. This new publicly traded company will hold assets unrelated to INBRX-101. INBRX-101 is an experimental drug currently in the second phase of clinical trials. It is designed to trea
JMP Securities analyst Reni Benjamin downgrades Inhibrx (NASDAQ:INBX) from Market Outperform to Market Perform.